-
DNA X raises $2.5M in Series B Preferred, cancels $3.1M debt to meet Nasdaq equity requirement
Sold 929,864 Series B Preferred shares for $2.5M cash and cancellation of $3.1M convertible note balance.
-
DNA X enters securities purchase agreement for $8.1M private placement of Series B Preferred Stock
DNA X agreed to issue 1,346,531 shares of Series B Convertible Preferred Stock at $6.00 per share to DNA Holdings Venture, Inc. for aggregate $8.1M.
-
DNA X terminates $500M equity line with Chardan Capital Markets
Terminated ChEF Purchase Agreement with Chardan Capital Markets, effective May 28, 2026.
-
DNA X receives Nasdaq delisting notice; issues $3.05M convertible note to insider
Nasdaq delisting notice due to stockholders' deficit of $983,000 as of March 31, 2026; hearing requested.
-
DNA X Q1 2026: asset sale nets $6.3M; no continuing revenue; raises $1.8M debt
Completed sale of mobile device assets to NEXA for $15M (net $13.5M after working capital adj); $12M paid, $1.5M due Oct 2026.
-
DNA X (SONM) dismisses auditor Baker Tilly, engages TAAD; 2025 audit includes going concern
Audit committee dismissed Baker Tilly on April 27, 2026; engaged TAAD LLP for fiscal 2026.
-
DNA X reports FY2025 no revenue from continuing ops; closes mobile asset sale for $15M
No revenue from continuing operations in Q4 2025; G&A expenses $1.2M primarily for acquisition and sale costs.
-
DNA X appoints Mike Mulica as acting CEO; salary $450k, 50k RSUs; CFO Crolius gets 35k RSUs
Mike Mulica appointed acting CEO effective Feb 9, 2026; base salary raised to $450,000 retroactive to Jan 30.
-
CEO Peter Liu and CCO Charles Becher resign; Scott Walker appointed to board
CEO Peter Liu resigned Jan 30, 2026, with $855,000 severance in two tranches ($427,500 each).
-
Sonim Technologies completes asset sale to NEXA, rebrands as DNA X, Inc., pivots to digital asset management
Asset sale of enterprise 5G solutions business to Pace Car Acquisition LLC (NEXA) closed Jan 23, 2026; post-closing cash ~$6.2M.
-
Sonim stockholders approve sale of Legacy Business to Pace Car Acquisition LLC
Stockholders approved Asset Purchase Agreement to sell Legacy Business (enterprise 5G solutions, rugged handsets, smartphones) to Pace Car Acquisition LLC.
-
Sonim issues $1.2M convertible note, acquires DNA X DeFi protocol for 19.99% stock
Issued $1.2M convertible promissory note to DNA Holdings, 10% interest, due Dec 2026, convertible at $5.50/share.
-
Sonim amends asset purchase agreement, removes reverse merger, adds payment condition
Removed all references to reverse merger (RTO) and related Form S-4 filing from the purchase agreement.
-
Sonim Q3 revenue $16.2M (+45% seq), net loss narrows to $4.8M; asset sale to NEXA for $15M on track for Q4 close
Net revenue $16.2M, up 45% sequentially from Q2; GAAP net loss $4.8M vs $7.5M in Q2.
-
Sonim appoints Executive Chairman, approves 1-for-18 reverse split; Nasdaq extension to Dec 31
Michael Mulica appointed Executive Chairman effective Oct 16, 2025; receives $300k salary, $250k annual RSU grant, and $500k RSU award tied to asset purchase with Social Mobile.
-
Sonim receives Nasdaq deficiency notice for low stockholders' equity of $1.334M
Nasdaq notified Sonim on Aug 22, 2025 that stockholders' equity of $1.334M as of June 30, 2025 is below the $2.5M minimum for continued listing.
-
Sonim receives Nasdaq deficiency notice for minimum bid price non-compliance
Nasdaq notified Sonim on Aug 13, 2025, that bid price closed below $1.00 for 30 consecutive business days.
-
Sonim enters €3M factoring at 15% discount, cuts warrant exercise price to $0.75
Entered factoring agreement with Tradewind GmbH; eligible receivables purchased at 15% discount; max financing €3M.
-
Sonim Q2 net loss $7.5M, revenue $11.2M; Social Mobile acquisition for $15M
GAAP net loss of $7.5M vs net income $0.5M in Q1; revenue $11.2M down 33% QoQ from $16.7M (incl. $5.3M one-time item).
-
Sonim sells enterprise 5G solutions business for $15M cash plus up to $5M earn-out; plans reverse merger
Purchase price $15M cash (subject to working capital adjustments) plus earn-out: 50% of net revenue above $70M in 12 months ending June 30, 2026, capped at $5M.
-
Sonim issues $2.755M secured note to Streeterville Capital; net proceeds $2.5M
Note carries 9% annual interest, matures 18 months from July 11, 2025; OID of $225K and $30K transaction fees.
-
Sonim Technologies prices public offering of 7.4M shares at $0.75, raising ~$4.9M net
Offering of 7,400,000 common shares at $0.75 per share closed July 2, 2025.
-
Sonim Technologies signs LOI for reverse takeover with AI HPC factory valued at ~$300M
Target is private US company building Nvidia-based HPC AI factories; valuation ~$300M supported by fairness opinion.
-
Sonim Technologies raises $1.375M via private placement of stock and warrants
1.1M shares of common stock and warrants for 550K shares sold for $1.375M total.
-
Sonim Q1 revenue $16.7M (+12% seq), GAAP net income $0.5M; adj EBITDA -$3.2M
Net revenue $16.7M, +12% sequentially; GAAP net income $0.5M vs Q4 2024 loss of $21.6M.
-
Sonim adopts poison pill in response to Orbic's $4.00/share takeover proposal; accelerates executive RSU vesting
Adopted limited-duration stockholder rights agreement triggered at 15.5% ownership (20% for passive investors), expiring April 21, 2026.
-
Sonim Technologies reports FY2024: Q4 revenue $15M (+12%), full year $58.3M (-38%)
Q4 revenue $15.0M (+12% YoY); full year revenue $58.3M (-38% YoY) due to strategic shift from white-label to own products.
-
Sonim Technologies forms special committee to evaluate strategic alternatives after AJP Holding 13D/A
Special Committee comprised of Mike Mulica (chair) and James Cassano, both independent directors.
-
Sonim Q4 preliminary: $15.2M revenue (+13% YoY), net loss $20-24M (vs $3M Q3), cash $5M
Revenue ~$15.2M, up 13% YoY from $13.4M and up sequentially from $15.0M in Q3.
-
Sonim Q2 revenue $11.5M, net loss $6.6M; expects H2 sequential growth
Net revenues of $11.5M, down from $16.8M in Q1 2024.
-
Sonim shareholders approve reverse stock split, authorized share increase, and equity plan expansion
Approved reverse stock split at ratio of 1-for-2 to 1-for-15, at Board discretion, within one year.